Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Randomized Sequence Open Label Expanded Safety and Acceptability Study of Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet and Rectally-Applied Tenofovir Reduced-Glycerin 1% Gel

NCT01687218 is registered in ClinicalTrials.gov with CONRAD as lead sponsor.

NCT NCT01687218
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01687218 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Randomized Sequence Open Label Expanded Safety and Acceptability Study of Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet and Rectally-Applied Tenofovir Reduced-Glycerin 1% Gel
Lead sponsor
CONRAD
Phase
Phase 2
Overall status
Completed
Start date
September 25, 2013
Completion date
May 26, 2015
Enrollment
195 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

hiv